Literature DB >> 34783229

Glioblastoma gene network reconstruction and ontology analysis by online bioinformatics tools.

Natalya V Gubanova1, Nina G Orlova2,3, Arthur I Dergilev4, Nina Y Oparina5, Yuriy L Orlov4,6.   

Abstract

Glioblastoma is the most aggressive type of brain tumors resistant to a number of antitumor drugs. The problem of therapy and drug treatment course is complicated by extremely high heterogeneity in the benign cell populations, the random arrangement of tumor cells, and polymorphism of their nuclei. The pathogenesis of gliomas needs to be studied using modern cellular technologies, genome- and transcriptome-wide technologies of high-throughput sequencing, analysis of gene expression on microarrays, and methods of modern bioinformatics to find new therapy targets. Functional annotation of genes related to the disease could be retrieved based on genetic databases and cross-validated by integrating complementary experimental data. Gene network reconstruction for a set of genes (proteins) proved to be effective approach to study mechanisms underlying disease progression. We used online bioinformatics tools for annotation of gene list for glioma, reconstruction of gene network and comparative analysis of gene ontology categories. The available tools and the databases for glioblastoma gene analysis are discussed together with the recent progress in this field.
© 2021 Natalya V. Gubanova et al., published by De Gruyter, Berlin/Boston.

Entities:  

Keywords:  drug search; gene networks; gene ontology; glioblastoma; medical genomics

Mesh:

Year:  2021        PMID: 34783229      PMCID: PMC8709738          DOI: 10.1515/jib-2021-0031

Source DB:  PubMed          Journal:  J Integr Bioinform        ISSN: 1613-4516


Introduction

Glioblastomas, along with astrocytomas, are the most common primary tumors of the central nervous system and make up approximately 60–70% of all pure brain tumors, challenging search for new therapy methods. Primary glioblastoma in 60% of cases occurs in people over 50 years old, while secondary glioblastoma is more characteristic for people under 45 years old [1, 2]. Glioblastoma is characterized by rapid infiltrative growth, the presence of foci of necrosis, a change in blood vessels. The lack of clear boundaries and the ability to relapse are a particular problem for surgical removal of the tumor, and for immunotherapy [3]. Primary central nervous system tumors are relatively rare and account for approximately 2% of all oncological diseases. However, tumors of the brain and spinal cord are the second most common form of malignancy in children after leukemia [4]. Glioblastoma has higher burden in survival of the patients with malignant brain tumors [5]. Despite the development in early detection, and treatment, 5-year glioblastoma survival only increased from 4 to 7% in past 4 decades [5]. Gliomas are the most common heterogeneous group of malignant tumors of the brain among the adult population, which differ in morphological characteristics, clinical course, and response to radio- and chemotherapy. The incidence of gliomas is 3–5: 100,000 of the adult population. In the treatment of glioblastoma with drugs, an obstacle is its resistance to a number of antitumor drugs initially, as well as the presence of a blood-brain barrier that negates the effectiveness of most chemotherapeutic agents and targeted drugs [3, 6]. For an object such as gliomas, it is necessary to conduct new studies based on modern cellular technologies, genome-wide technologies for high-throughput sequencing, and the integration of available information from international databases and genomic projects [7, 8]. The practical task was to construct (collect) a list of genes associated with the development of glioblastoma, analyze the categories of gene ontologies for such a list, and reconstruct the gene network. For key genes of the disease, obtained by analyzing the structure of the gene network, options for searching for drugs (substances that interact with this protein) will be considered. There are open international databases on gene expression including glioblastoma (microarrays and sequencing data of GEO NCBI, http://www.ncbi.nlm.nih.gov/geoprofiles/), expression in various types of tumor cells (The Cancer Gene Atlas, cancergenome.nih.gov), gene expression for brain compartments (Allen Brain Atlas), protein interactions databases such as HPRD (http://hprd.org/), KEGG biochemical reactions (http://www.genome.jp/kegg/), Interactome (http://interactome.org/), sequenced tumor genomes, including gliomas and glioblastomas (https://cghub.ucsc.edu/). The Allen Institute has developed the Ivy Glioblastoma Atlas Project database (http://glioblastoma.alleninstitute.org/) according to patients with glioma. We demonstrate that these publicly available online bioinformatics tools can give helpful information for annotation of gene list for glioblastoma, reconstruction of gene network and comparative analysis of the related diseases. This approach for gene network analysis of list of gene names using online bioinformatics tools presents application of bioinformatics methods to annotation of complex human diseases.

Methods

Obtaining a list of genes associated with a hereditary predisposition to glioblastoma. The Internet resource OMIM (Online Mendelian Inheritance in Man) (https://omim.org/, access date 10.10.2021) was used to analyze the genes of Mendelian inheritance in humans [9]. Search for the keyword ‘glioblastoma’ gave 264 genes. As a result, 264 gene names (official gene symbols) were obtained (ADAM10, ADAM17, ADAM9, ADGRB1, etc., see the Supplement). Next, we used DAVID (Database for Annotation, Visualization and Integrated Discovery) tool (https://david.ncifcrf.gov/summary.jsp) [10] and the PANTHER (Protein ANalysis THrough Evolutionary Relationships) (http://pantherdb.org/) resource [11] for gene ontology analysis. Then we applied gene network reconstruction tools described in the next sections. The workflow of the data processing is presented in Figure 1.
Figure 1:

Workflow for information data processing for glioblastoma genes.

Workflow for information data processing for glioblastoma genes. Figure 1 shows main steps of data processing. Data collection starts from the OMIM database (https://omim.org/) and GeneCards (https://www.genecards.org/) resources. At next step gene ontology analysis tools PANTHER and DAVID are used as well as g:Profiler (http://biit.cs.ut.ee/gprofiler/gost) online tool. Then STRING-DB (https://string-db.org) and GeneMANIA (https://genemania.org/) online applications help in the network reconstruction and visualization. Finally MalaCards (https://www.malacards.org/) and ToppGene (https://toppgene.cchmc.org/) allow find disease-disease interactions and prioritize genes in the list.

Results

We have analyzed gene ontology categories for the same gene list obtained by different online bioinformatics tools. DAVID [10] and the PANTHER resource [11] were used to estimate the categories of gene ontologies.

Comparison of gene ontology categories

A list of 264 human genes was loaded through the DAVID interface to search for relevant categories of gene ontologies for this group of genes. 255 identifiers were used next (the Functional Annotation Chart option). The table was limited to values of normalized p-value <0.00001 (or, in power notation, <1.0 × 10−5) (Bonferroni correction). We deleted categories (table rows) for groups of less than eight genes, and Fold enrichment (observed number of genes/expected) less than 2. As can be seen from Table 1, the most significant GO categories for glioblastoma genes are protein binding, positive regulation of protein phosphorylation, membrane location (according to cellular compartments – GOTERM_CC classification), and kinase activity. In general, according to the categories from the table, membrane proteins and kinases play an important role, apparently associated with signal transduction into the cell. UP_KEYWORD (terms from UniProt (https://www.uniprot.org/) shows associations with tumors and kinase activity.
Table 1:

Categories of gene ontologies for glioblastoma genes according to DAVID

Category setTerm# genesFoldBonferroni
UP_KEYWORDSTumor suppressor24121.3 × 10−15
UP_KEYWORDSPhosphoprotein1541.63.0 × 10−13
UP_KEYWORDSDisease mutation712.51.2 × 10−10
GOTERM_MF_DIRECTProtein binding1641.54.2 × 10−10
GOTERM_BP_DIRECTNegative regulation of cell proliferation2651.8 × 10−7
INTERPROProtein kinase-like domain284.32.1 × 10−7
GOTERM_BP_DIRECTPositive regulation of protein phosphorylation169.62.5 × 10−7
GOTERM_MF_DIRECTProtein kinase binding2452.6 × 10−7
UP_KEYWORDSKinase313.73.1 × 10−7
UP_KEYWORDSProto-oncogene186.74.4 × 10−7
UP_KEYWORDSCell cycle273.76.6 × 10−6
UP_KEYWORDSTyrosine-protein kinase129.51.5 × 10−5
INTERPROProtein kinase, catalytic domain2441.8 × 10−5
UP_SEQ_FEATUREBinding site:ATP253.93.2 × 10−5
GOTERM_MF_DIRECTKinase activity175.54.0 × 10−5
UP_SEQ_FEATUREActive site:Proton acceptor273.56.8 × 10−5
GOTERM_BP_DIRECTProtein phosphorylation2447.7 × 10−5
GOTERM_MF_DIRECTProtein kinase activity204.38.7 × 10−5
GOTERM_CC_DIRECTMembrane5629.6 × 10−5
Categories of gene ontologies for glioblastoma genes according to DAVID Gene ontologies were analyzed for the same list of genes using the PANTHER resource (Protein ANalysis THrough Evolutionary Relationships) [11]. Table 2 of ontologies for categories of biological processes was built using PANTHER.
Table 2:

Categories of gene ontologies for glioblastoma genes according to PANTHER (biological process).

GO categories (biological process complete)# genesFold enrich. p value
Negative regulation of biological process1462.362.21 × 10−25
Negative regulation of cellular process1372.402.20 × 10−23
Anatomical structure development1362.285.27 × 10−21
System development1232.477.48 × 10−21
Regulation of cell population proliferation753.813.21 × 10−20
Developmental process1422.141.42 × 10−19
Regulation of signaling1022.621.39 × 10−17
Regulation of cell differentiation673.753.90 × 10−17
Regulation of cell death693.634.97 × 10−17
Regulation of apoptotic process643.763.44 × 10−16
Cellular developmental process1032.494.11 × 10−16
Regulation of programmed cell death643.689.59 × 10−16
Regulation of signal transduction912.663.02 × 10−15
Regulation of cellular component movement534.333.48 × 10−15
Nervous system development782.985.86 × 10−15
Regulation of epithelial cell proliferation327.931.10 × 10−14
Positive regulation of phosphorus metabolic process474.441.96 × 10−13
Immune system development405.041.21 × 10−12
Regulation of nervous system development336.311.69 × 10−12
Generation of neurons533.597.61 × 10−12
Categories of gene ontologies for glioblastoma genes according to PANTHER (biological process). In total, 238 identifiers were recognized from the same list of genes, the others were not recognized or could not be unambiguously mapped. In total, 20,595 genes were used in the PANTHER reference genome (15 October 2021). We limited the output to p-values up to 10−12 (after Bonferroni correction) and Fold enrichment greater than two to represent the most informative results. Table 2 shows that the most significant categories for glioblastoma genes are negative regulation of biological processes, developmental processes, generation of neurons, and cell proliferation. The categories of processes related to the development of the nervous system are also presented (this is expected, since glioblastoma is a brain disease). Further, the categories of gene ontologies for molecular functions and cellular compartments were calculated using PANTHER (Table 3). The threshold for the significance of the categories was taken already at the 10−3 level (after the Bonferroni correction).
Table 3:

Categories of gene ontologies for glioblastoma genes according to PANTHER (molecular functions and cellular compartments).

# genesFold enrich. p value
GO categories – molecular function complete
Protein binding2251.317.98 × 10−13
Enzyme binding682.762.84 × 10−8
Kinase binding363.941.54 × 10−8
Phosphotransferase activity alcohol group as acceptor313.761.57 × 10−6
Protein tyrosine kinase activity148.201.61 × 10−5
Transferase activity transferring phosphorus-containing groups343.092.78 × 10−5
Beta-catenin binding98.665.97 × 10−3
Growth factor receptor binding116.496.20 × 10−3
GO categories – cellular component complete
Organelle lumen1151.746.06 × 10−8
Cytosol1111.723.16 × 10−7
Cell junction592.358.77 × 10−7
Cell projection632.231.75 × 10−6
Categories of gene ontologies for glioblastoma genes according to PANTHER (molecular functions and cellular compartments). The results for cellular components show that the most significant categories for glioblastoma genes are organelles, cell junction. It may be associated with signal transmission between cells and refers to neurons. Thus, both DAVID and PANTHER for glioblastoma genes support the categories of gene ontologies of protein binding, membranes, cell adhesion, and intercellular contacts. Note that direct comparison of DAVID and PANTHER tools proved be limited due to different database version and genome annotation versions [12]. Other available resources for calculating gene ontologies – GeneOntology (http://geneontology.org/) and g:Profiler GOST (http://biit.cs.ut.ee/gprofiler/), which are not presented in this study, can also be used.

Reconstruction of gene networks for glioblastoma genes

To reconstruct the gene network of interactions between glioblastoma genes, the resources of GeneMANIA (https://genemania.org/) and STRING-DB (https://string-db.org/) were used. The following Figure 2 shows the glioblastoma gene network reconstructed with GeneMANIA and STRING-DB.
Figure 2:

Gene network for glioblastoma genes reconstructed by STRING-DB.

Gene network for glioblastoma genes reconstructed by STRING-DB. In the centre of the network there are the genes (proteins) of glioblastoma, which have a large number of connections with other elements – PTRN, TP53, KRAS. Consider the results of network reconstruction using STRING-DB (https://string-db.org/) for the same list of glioblastoma genes (Figure 2). It can be seen that the network is quite sparse, some objects (proteins) do not contact others. A central, strongly linked cluster of genes is highlighted. In total, 243 genes from the list were recognized by STRING-DB. Statistics on STING-DB show that the network has a reasonably large number of connections (with a significance <1.0 × 10−16), the average degree of connectivity of the network node (protein) is 13.6, the clustering coefficient is 0.5. The drawing from the STING-DB was iteratively rebuilt with the removal of unrelated genes and the replacement of several colored connections between the nodes of the network – with one line (confidence), taking into account only experimentally proven interactions. Than we increase parameter ‘confidence level’ to keep only verified links in the network. The figure shows several hubs of the network – the largest includes genes RBBP4, AKT1, MTOR, KRAS, STAT3, PTEN, several smaller, but also connected in a common network of clusters, the largest number of connections in the TP53 gene (a well-known oncogene) can be seen. In general, the analysis of the structure of the gene network for glioblastoma genes shows the existence of a dense, connected, sufficiently large cluster of genes (network nodes) including known oncogenes, such as TP53. Thus, standard online bioinformatics tools allow to model main parameters of gene network related to given disease. This approach is quite useful in distant education for medical students due to open access tools, fast visualization, interactive user interface not demanding programming. Integration of the results obtained by online bioinformatics tools and genetics data leads to novel knowledge in the study of complex oncological diseases.

Related works

Let’s consider functional annotation of the glioblastoma genes using different data sources and their combinations. According to GeneCards (genecards.org), the following 20 genes are the most significant. Table 4 shows large fraction of non-protein coding genes in the list. The score in the table column show relevance of the gene to the search query to the literature database (https://www.genecards.org/Guide/Search#relevance). Lager the GeneCards score, higher relevance to the disease is. GeneCards Inferred Functionality Scores (GIFtS) parameter shows gene functionality annotated in the databases (https://www.genecards.org/Guide/GeneCard#GIFtS) [13]. Note that the hub genes in the network have high functionality, while RNA less annotated and included in standard gene network (in STRING-DB).
Table 4:

Gene list for glioblastoma by GeneCards.

SymbolDescriptionCategoryGIFtSRelevance score
1TP53Tumor protein P53Protein coding5252.29
2EGFREpidermal growth factor receptorProtein coding5240.05
3IDH1Isocitrate dehydrogenase (NADP(+)) 1Protein coding5138.95
4MSH2MutS homolog 2Protein coding4833.76
5MGMTO-6-Methylguanine-DNA methyltransferaseProtein coding4831.36
6ERBB2Erb-B2 receptor tyrosine kinase 2Protein coding5229.57
7MIR21MicroRNA 21RNA gene2428.37
8BRCA2BRCA2 DNA repair associatedProtein coding4827.59
9PTENPhosphatase and tensin homologProtein coding5126.68
10PIK3CAPhosphatidylinositol-4,5-bisphosphate 3-kinaseProtein coding5225.74
catalytic subunit alpha
11MIR221MicroRNA 221RNA gene2124.00
12MIR222MicroRNA 222RNA gene2123.89
13FGFR1Fibroblast growth factor receptor 1Protein coding5322.81
14MIR34AMicroRNA 34aRNA gene2222.63
15MIR296MicroRNA 296RNA gene1722.51
16H3-3AH3.3 histone AProtein coding3421.76
17MIR137MicroRNA 137RNA gene1944.398
18IDH2Isocitrate dehydrogenase (NADP(+)) 2Protein coding5120.63
19PPARGPeroxisome proliferator activated receptor gammaProtein coding5120.37
20MIR326MicroRNA 326RNA gene2120.14
Gene list for glioblastoma by GeneCards. Prioritization of genes was performed using the resource ToppGene: Candidate gene prioritization (https://toppgene.cchmc.org) [14]. The genes presented were found to be associated with the following diseases (Table 5).
Table 5:

Diseases found by prioritization of shared genes to glioblastoma.

No.DescriptionCategoryScore
1Glioma1.882 × 10−25 9.333 × 10−22
2Pilocytic astrocytoma3.147 × 10−25 1.561 × 10−21
3–4Adult pilocytic astrocytoma/childhood pilocytic astrocytoma1.829 × 10−22 9.069 × 10−19
5Malignant glioma3.741 × 10−21 1.855 × 10−17
6Mixed gliomas3.741 × 10−21 1.855 × 10−17
7Neurofibromatosis 16.750 × 10−21 3.348 × 10−17
8Malignant neoplasm of soft tissue2.560 × 10−20 1.270 × 10−16
9Ganglioglioma4.231 × 10−20 2.098 × 10−16
10–11Childhood oligodendroglioma/adult oligodendroglioma4.616 × 10−20 2.290 × 10−16
12Sarcoma2.272 × 10−19 1.127 × 10−15
Diseases found by prioritization of shared genes to glioblastoma. One can see in the table relevant diseases categories related to brain, glioma types and soft tissues cancers. The approaches of gene ontology analysis and gene network reconstruction using similar bioinformatics tools to search for glioma hub genes are published in series of papers. In recent work by [15] hub genes in the tumor microenvironment were identified using TCGA data. The hub genes for glioblastoma were identified by the Cytoscape tool (https://cytoscape.org/), and pathway enrichment analysis of the genes was performed using Database for Annotation, Visualization and Integrated Discovery (DAVID). Functional enrichment analysis identified set of upregulated and downregulated cross genes, which were mainly linked to immune response, inflammatory response, cell membrane, and receptor activity. Li and co-authors [16] used weighted gene co-expression network analysis to define hub genes. Gene Set Enrichment Analysis (GSEA) identified further hub genes-related pathways. The Cancer Genome Atlas (TCGA) database was used to identify differentially expressed genes [17]. Then Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to determine the related functions and pathways of these genes. Such analysis can lead to the identification of potential target genes and related drugs. Yang and Yang [18] recently analyzed glioma genes by GSEA, and the significantly enriched KEGG pathways involved in synapse signaling and oxytocin signaling pathways. The core molecules of GBM and the DrugBank database were assessed to identify 10 drugs included tetrachlorodecaoxide related to cancer and neuropsychiatric diseases [18].

Conclusions

After years of intensive research glioblastoma remains a dangerous disease with a low survival rate. The existing methods of therapy (chemotherapy, radio- and immunotherapy) can prolong the patient’s life without remission and glioblastoma data integration and analysis can lead to promising therapeutic targets [19]. The study of the structure of the gene network shows a high connectivity of genes and their products. Glioma progression is strongly connected with different types of epigenetic phenomena, such as histone modifications, DNA methylation, chromatin remodeling, and aberrant microRNA [18]. Amid the epigenetic therapies, histone deacetylase inhibitors (HDACIs) and DNA methyltransferase inhibitors have been used for treating tumors [20]. Long non-coding RNAs, circular RNAs, and transcribed pseudogenes act as ceRNA (competing endogenous RNA) to regulate the expression of related genes by sponging the shared microRNAs [21]. Circular (circ)RNAs serve important roles in the development and progression of glioma and may have potential as therapeutic targets too [22]. A set of glioma-related genes obtained from the Comparative Toxicogenomics Database were predicted to be regulated by 15 miRNAs via the miRwalk 2.0 database [22]. Zhu and colleagues [23] provided a framework of workflow for potential therapeutic drug discovery and predicted 10 potential drugs for glioblastoma therapy. Effectiveness of drugs has to be tested on the experimental models [24]. Chemotherapy for glioblastoma remains ineffective due to insufficient penetration of therapeutic agents into the tumor [25]. Recent works show limits on the isotope distribution in tissues in a glioma xenograft animal model [26]. An analysis of the literature (PubMed) showed continued growth of publications on the topic – there are about 54 thousand publications up to date. Integration of large biological databases and re-analysis, combination of different tools allows keeping current structure of the disease description and annotation, as we have discussed at the international conferences series on computational genomics [27, 28]. Network analysis of interacting genes shows existing gene clusters in the network, and potential new targets for therapy [29]. Overall, such application of available bioinformatics tools for gene list analysis could serve as a standard for education [30, 31], allows to reveal novel features for cancer diseases. The network analysis complements analysis of microarray gene expression and transcriptomics data for glioblastoma research [7, 32]. The network modelling using the described tools proved to be fruitful in other complex disease analysis, such as Parkinson disease, mental disorders, and diabetes [33, 34]. Click here for additional data file.
  33 in total

1.  DAVID: Database for Annotation, Visualization, and Integrated Discovery.

Authors:  Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-04-03       Impact factor: 13.583

2.  Analysis of differential gene expression by RNA-seq data in brain areas of laboratory animals.

Authors:  Vladimir N Babenko; Anatoly O Bragin; Anastasia M Spitsina; Irina V Chadaeva; Elvira R Galieva; Galina V Orlova; Irina V Medvedeva; Yuriy L Orlov
Journal:  J Integr Bioinform       Date:  2016-12-18

Review 3.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

4.  [Reconstruction of gene network associated with Parkinson disease for gene targets search].

Authors:  Y L Orlov; A G Galieva; N G Orlova; E N Ivanova; Y A Mozyleva; A A Anashkina
Journal:  Biomed Khim       Date:  2021-05

5.  Multiregional Sequencing of IDH-WT Glioblastoma Reveals High Genetic Heterogeneity and a Dynamic Evolutionary History.

Authors:  Sara Franceschi; Prospero Civita; Francesco Pasqualetti; Francesca Lessi; Martina Modena; Serena Barachini; Mariangela Morelli; Orazio Santonocito; Riccardo Vannozzi; Geoffrey J Pilkington; Valerio Ortenzi; Antonio Giuseppe Naccarato; Paolo Aretini; Chiara Maria Mazzanti
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

6.  Computer Analysis of Glioma Transcriptome Profiling: Alternative Splicing Events.

Authors:  Vladimir N Babenko; Natalya V Gubanova; Anatoly O Bragin; Irina V Chadaeva; Gennady V Vasiliev; Irina V Medvedeva; Alexey S Gaytan; Alexey L Krivoshapkin; Yuriy L Orlov
Journal:  J Integr Bioinform       Date:  2017-09-18

7.  Circular RNA hsa_circ_0005114-miR-142-3p/miR-590-5p-adenomatous polyposis coli protein axis as a potential target for treatment of glioma.

Authors:  Bo Wei; Le Wang; Jingwei Zhao
Journal:  Oncol Lett       Date:  2020-11-19       Impact factor: 2.967

8.  GIFtS: annotation landscape analysis with GeneCards.

Authors:  Arye Harel; Aron Inger; Gil Stelzer; Liora Strichman-Almashanu; Irina Dalah; Marilyn Safran; Doron Lancet
Journal:  BMC Bioinformatics       Date:  2009-10-23       Impact factor: 3.169

9.  Biological Big Bytes: Integrative Analysis of Large Biological Datasets.

Authors:  Ming Chen; Andrew Harrison; Hugh Shanahan; Yuriy Orlov
Journal:  J Integr Bioinform       Date:  2017-09-13

10.  Development of an Immune-Related Prognostic Index Associated With Glioblastoma.

Authors:  Zhengye Jiang; Yanxi Shi; Wenpeng Zhao; Yaya Zhang; Yuanyuan Xie; Bingchang Zhang; Guowei Tan; Zhanxiang Wang
Journal:  Front Neurol       Date:  2021-05-19       Impact factor: 4.003

View more
  1 in total

1.  Special Issue of the 1st International Applied Bioinformatics Conference (iABC'21).

Authors:  Jens Allmer; Mourad Elloumi; Matteo Comin; Ralf Hofestädt
Journal:  J Integr Bioinform       Date:  2021-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.